188 related articles for article (PubMed ID: 28906028)
21. Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.
Giraldi E; Provenzi M; Conter V; Colledan M; Bolognini S; Foglia C; Sebastiani R; Fiocchi R; Gianatti A; DʼAntiga L; Rambaldi A
Transplantation; 2016 Feb; 100(2):437-45. PubMed ID: 26270449
[TBL] [Abstract][Full Text] [Related]
22. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
23. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
24. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor.
Nieto-Rios JF; Gómez de Los Ríos SM; Serna-Higuita LM; Ocampo-Kohn C; Aristizabal-Alzate A; Gálvez-Cárdenas KM; Zuluaga-Valencia GA
Colomb Med (Cali); 2016 Dec; 47(4):196-202. PubMed ID: 28293043
[TBL] [Abstract][Full Text] [Related]
25. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
[TBL] [Abstract][Full Text] [Related]
26. Use of Rituximab for persistent EBV DNAemia, and Its effect on donor-specific antibody development in pediatric renal transplant recipients: A case series.
Puliyanda DP; Jordan SC; Kim IK; Patel M; Murthy A; Huang E; Zhang X; Reinsmoen N; Kamil ES; Toyoda M
Pediatr Transplant; 2021 Dec; 25(8):e14113. PubMed ID: 34418254
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
28. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
[TBL] [Abstract][Full Text] [Related]
29. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
30. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
[TBL] [Abstract][Full Text] [Related]
31. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.
Traum AZ; Rodig NM; Pilichowska ME; Somers MJ
Pediatr Transplant; 2006 Jun; 10(4):505-12. PubMed ID: 16712612
[TBL] [Abstract][Full Text] [Related]
32. Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience.
Nakanishi C; Kawagishi N; Sekiguchi S; Akamatsu Y; Sato K; Miyagi S; Takeda I; Fukushima D; Kobayashi Y; Ishida K; Niizuma H; Tsuchiya S; Wada M; Nio M; Satomi S
Surg Today; 2012 Aug; 42(8):741-51. PubMed ID: 22278621
[TBL] [Abstract][Full Text] [Related]
33. Prompt diagnosis and management of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytosis: A dreaded complication in a post-liver transplant child.
Jha B; Mohan N; Gajendra S; Sachdev R; Goel S; Sahni T; Raina V; Soin A
Pediatr Transplant; 2015 Nov; 19(7):E177-80. PubMed ID: 26184957
[TBL] [Abstract][Full Text] [Related]
34. Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease.
Weiner C; Weintraub L; Wistinghausen B; Tomaino J; Arnon R; Kerkar N; Miloh T
Pediatr Transplant; 2012 Aug; 16(5):458-64. PubMed ID: 22554096
[TBL] [Abstract][Full Text] [Related]
35. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series.
Montanari F; Radeski D; Seshan V; Alobeid B; Bhagat G; O'Connor OA
Br J Haematol; 2015 Nov; 171(4):491-500. PubMed ID: 26250758
[TBL] [Abstract][Full Text] [Related]
36. Eosinophilic esophagitis in children following cardiac transplantation: association with post-transplant lymphoproliferative disorder and other transplant outcomes.
Kindel SJ; Joy BF; Pahl E; Wald EL
Pediatr Transplant; 2014 Aug; 18(5):491-6. PubMed ID: 24931365
[TBL] [Abstract][Full Text] [Related]
37. Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: A multicenter analysis.
West SC; Friedland-Little JM; Schowengerdt KO; Naftel DC; Pruitt Freeze E; Smith KS; Urschel S; Michaels MG; Kirklin JK; Feingold B
Clin Transplant; 2019 May; 33(5):e13521. PubMed ID: 30861200
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
Birkeland SA; Hamilton-Dutoit S; Bendtzen K
Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M
Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
[TBL] [Abstract][Full Text] [Related]
40. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
